S6E7: Next-Gen Lipid-Lowering Strategies: ANGPTL4 Inhibitor Clinical Insights
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
S6E7: Next-Gen Lipid-Lowering Strategies: ANGPTL4 Inhibitor Clinical Insights
-
Narrated by:
-
By:
In this episode, Alan Brown, MD, MHA, MNLA sits down with Rebecca Juliano, PhD, MPhil, MA to discuss a first-in-human study of an investigational ANGPTL4 inhibitory antibody. The conversation explores how this novel therapeutic approach safely and effectively reduces plasma triglycerides and remnant cholesterol—key drivers of residual cardiovascular risk. Listeners will gain insight into the mechanism of action, clinical significance, and potential role of ANGPTL4 inhibition in the evolving landscape of lipid management.
View this Episode on YouTube HERE
Guests
Rebecca Juliano, PhD, MPhil, MA
Chief Development Officer
Marea Therapeutics
San Francisco, CA
No reviews yet